TR200400653T4 - Farmasötik kompozisyonlar. - Google Patents
Farmasötik kompozisyonlar.Info
- Publication number
- TR200400653T4 TR200400653T4 TR2004/00653T TR200400653T TR200400653T4 TR 200400653 T4 TR200400653 T4 TR 200400653T4 TR 2004/00653 T TR2004/00653 T TR 2004/00653T TR 200400653 T TR200400653 T TR 200400653T TR 200400653 T4 TR200400653 T4 TR 200400653T4
- Authority
- TR
- Turkey
- Prior art keywords
- buprenorphine
- naloxone
- nalmefene
- amount
- naltrexone
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 4
- 229960001736 buprenorphine Drugs 0.000 abstract 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 4
- 229960004127 naloxone Drugs 0.000 abstract 4
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 abstract 3
- 229960005297 nalmefene Drugs 0.000 abstract 3
- 230000000202 analgesic effect Effects 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 229960003086 naltrexone Drugs 0.000 abstract 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9927359.1A GB9927359D0 (en) | 1999-11-19 | 1999-11-19 | Improvements in or relating to organic compositions |
| US17620800P | 2000-01-14 | 2000-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200400653T4 true TR200400653T4 (tr) | 2004-04-21 |
Family
ID=26316086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2004/00653T TR200400653T4 (tr) | 1999-11-19 | 2000-11-17 | Farmasötik kompozisyonlar. |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US6995169B2 (OSRAM) |
| EP (1) | EP1242087B1 (OSRAM) |
| JP (1) | JP4745576B2 (OSRAM) |
| KR (1) | KR100726699B1 (OSRAM) |
| CN (1) | CN100431543C (OSRAM) |
| AR (1) | AR031682A1 (OSRAM) |
| AT (1) | ATE262335T1 (OSRAM) |
| AU (1) | AU777259B2 (OSRAM) |
| BR (1) | BR0015580A (OSRAM) |
| CA (1) | CA2392013C (OSRAM) |
| CO (1) | CO5261517A1 (OSRAM) |
| CZ (1) | CZ303160B6 (OSRAM) |
| DE (1) | DE60009346T2 (OSRAM) |
| DK (1) | DK1242087T3 (OSRAM) |
| ES (1) | ES2214334T3 (OSRAM) |
| GB (1) | GB2356348B (OSRAM) |
| HU (1) | HU229565B1 (OSRAM) |
| IL (2) | IL149580A0 (OSRAM) |
| MX (1) | MXPA02004978A (OSRAM) |
| NO (1) | NO321965B1 (OSRAM) |
| NZ (1) | NZ519023A (OSRAM) |
| PL (1) | PL199727B1 (OSRAM) |
| PT (1) | PT1242087E (OSRAM) |
| RO (1) | RO121174B1 (OSRAM) |
| RU (1) | RU2255737C2 (OSRAM) |
| SI (1) | SI21025B (OSRAM) |
| SK (1) | SK286888B6 (OSRAM) |
| TR (1) | TR200400653T4 (OSRAM) |
| TW (1) | TW550070B (OSRAM) |
| WO (1) | WO2001035942A2 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| CA2569958C (en) | 2004-06-12 | 2016-03-22 | Jane C. Hirsh | Abuse-deterrent drug formulations |
| JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| CA2674915C (en) * | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
| US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
| US8093261B2 (en) | 2006-10-24 | 2012-01-10 | The Johns Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
| MX343867B (es) * | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
| GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
| GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
| GB2447015A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| GB2447014A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| MX2010002409A (es) * | 2007-09-03 | 2010-05-19 | Nanotherapeutics Inc | Composiciones y metodos para la distribucion de farmacos escasamente solubles. |
| US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| EP2523557B1 (en) | 2010-01-11 | 2019-09-25 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| CN104873455B (zh) | 2010-12-22 | 2023-09-12 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| EP2915525B1 (en) | 2011-09-19 | 2021-08-11 | Orexo AB | Sublingual abuse-resistant tablets comprising buprenorphine and naloxone |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| CN104955483A (zh) | 2013-01-30 | 2015-09-30 | 法莫斯医疗公司 | 用低剂量药剂治疗抑郁症和其它疾病 |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| DK3043777T3 (da) | 2013-09-10 | 2020-07-20 | Fresh Cut Dev Llc | Sublingual buprenorphinspray |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| SG10201809280PA (en) * | 2014-04-22 | 2018-11-29 | Otsuka Pharma Co Ltd | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
| WO2021158957A1 (en) * | 2020-02-05 | 2021-08-12 | Summit Biosciences Inc. | Drug products for intranasal administration and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8430109D0 (en) | 1984-11-29 | 1985-01-09 | Gkn Technology Ltd | Securing components |
| GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| GB2213058B (en) * | 1987-12-03 | 1991-07-17 | Reckitt & Colmann Prod Ltd | Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| RU2077326C1 (ru) * | 1992-12-29 | 1997-04-20 | Ярыгин Владимир Никитич | Препарат для анальгезии |
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| JP2004501094A (ja) * | 2000-05-05 | 2004-01-15 | ペイン・セラピューティクス・インコーポレイテッド | オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法 |
-
2000
- 2000-11-16 AR ARP000106062A patent/AR031682A1/es unknown
- 2000-11-17 PT PT00977658T patent/PT1242087E/pt unknown
- 2000-11-17 NZ NZ519023A patent/NZ519023A/en not_active IP Right Cessation
- 2000-11-17 CN CNB008159181A patent/CN100431543C/zh not_active Expired - Fee Related
- 2000-11-17 DE DE60009346T patent/DE60009346T2/de not_active Expired - Lifetime
- 2000-11-17 BR BR0015580-2A patent/BR0015580A/pt not_active Application Discontinuation
- 2000-11-17 EP EP00977658A patent/EP1242087B1/en not_active Expired - Lifetime
- 2000-11-17 RO ROA200200620A patent/RO121174B1/ro unknown
- 2000-11-17 TR TR2004/00653T patent/TR200400653T4/xx unknown
- 2000-11-17 MX MXPA02004978A patent/MXPA02004978A/es active IP Right Grant
- 2000-11-17 DK DK00977658T patent/DK1242087T3/da active
- 2000-11-17 WO PCT/GB2000/004372 patent/WO2001035942A2/en not_active Ceased
- 2000-11-17 GB GB0028088A patent/GB2356348B/en not_active Expired - Fee Related
- 2000-11-17 HU HU0203588A patent/HU229565B1/hu not_active IP Right Cessation
- 2000-11-17 SK SK876-2002A patent/SK286888B6/sk not_active IP Right Cessation
- 2000-11-17 ES ES00977658T patent/ES2214334T3/es not_active Expired - Lifetime
- 2000-11-17 SI SI200020061A patent/SI21025B/sl not_active IP Right Cessation
- 2000-11-17 CZ CZ20022121A patent/CZ303160B6/cs not_active IP Right Cessation
- 2000-11-17 RU RU2002116361/15A patent/RU2255737C2/ru not_active IP Right Cessation
- 2000-11-17 IL IL14958000A patent/IL149580A0/xx active IP Right Grant
- 2000-11-17 JP JP2001537935A patent/JP4745576B2/ja not_active Expired - Fee Related
- 2000-11-17 CA CA002392013A patent/CA2392013C/en not_active Expired - Fee Related
- 2000-11-17 AT AT00977658T patent/ATE262335T1/de active
- 2000-11-17 PL PL355330A patent/PL199727B1/pl unknown
- 2000-11-17 AU AU15297/01A patent/AU777259B2/en not_active Ceased
- 2000-11-17 CO CO00087459A patent/CO5261517A1/es active IP Right Grant
- 2000-11-17 KR KR1020027006375A patent/KR100726699B1/ko not_active Expired - Fee Related
-
2001
- 2001-01-29 TW TW090101624A patent/TW550070B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 IL IL149580A patent/IL149580A/en not_active IP Right Cessation
- 2002-05-14 US US10/145,284 patent/US6995169B2/en not_active Expired - Fee Related
- 2002-05-15 NO NO20022330A patent/NO321965B1/no not_active IP Right Cessation
-
2005
- 2005-10-20 US US11/254,602 patent/US7402591B2/en not_active Expired - Fee Related
- 2005-10-20 US US11/254,988 patent/US20060058333A1/en not_active Abandoned
- 2005-10-20 US US11/254,525 patent/US20060069113A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200400653T4 (tr) | Farmasötik kompozisyonlar. | |
| NZ508526A (en) | Opioid formulations for treating pain | |
| TR199800777T2 (xx) | Zay�f ��z�n�rl��e sahip bazik ila�lar i�in kontroll� salma form�lasyon. Zay�f ��z�n�rl��e sahip bazik ila�lar i�in kontroll� salma form�lasyonu. | |
| NO996310L (no) | Sammensetninger og fremgangsmÕter for Õ redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser | |
| EP0429039A3 (en) | Use of an opiate antagonist for the preparation of a pharmaceutical composition to be transdermally administered, and device for transdermal delivery | |
| MXPA02007690A (es) | Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide. | |
| JP2003514013A5 (OSRAM) | ||
| ATE419039T1 (de) | Pharmazeutische kombinationen von oxycodon und naloxon | |
| SI1041987T1 (sl) | Farmacevtska oralna dozirna oblika, ki obsega kombinacijo opioidnega agonista in naltreksona | |
| IE893455L (en) | Dosage form having reduced abuse potential | |
| KR960700061A (ko) | 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence) | |
| TR200103613T2 (tr) | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. | |
| RU2000126790A (ru) | Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса | |
| KR910019618A (ko) | 발기부전증 치료용 제약 조성물 | |
| KR880002515A (ko) | 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물 | |
| JP2004507496A5 (OSRAM) | ||
| JP2002523370A5 (OSRAM) | ||
| KR970025615A (ko) | 암 전이 억제제 | |
| CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
| PT975348E (pt) | Composicoes de tibolona estabilizadas | |
| EA200200914A1 (ru) | Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина | |
| KR900011461A (ko) | 트립스타틴을 유효성분으로 하는 치료제 | |
| PT1058544E (pt) | Inibicao da actividade do tnf | |
| NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer | |
| MXPA02006034A (es) | Formas de dosis mucosaloral de apomorfina. |